Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cardiol Therapeutics Inc. T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Cardiol Therapeutics’ lead product, CardiolRx™, is an oral pharmaceutical that is currently being evaluated in the Phase II multi-national ARCHER trial in patients presenting with acute myocarditis. Cardiol has received IND authorization from the FDA to conduct a clinical study to evaluate CardiolRx™ in a Phase II multi-center open-label pilot study in recurrent pericarditis. Cardiol is developing a subcutaneously administered drug formulation of cannabidiol intended for use in heart failure.


TSX:CRDL - Post by User

User Avatar Image
(6)
•••
  • NorthBuddyX
Post by NorthBuddyon Nov 11, 2022 5:32pm
220 Views
Post# 35092766

Peeps liked the filing

Peeps liked the filingThe boys is doing it,
https://quantisnow.com/insight/3668667

https://www.youtube.com/watch?v=bQDC_wuJ6j0&ab_channel=TBILISELICOLCHI
<< Previous
Bullboard Posts
Next >>